<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601873</url>
  </required_header>
  <id_info>
    <org_study_id>CTVS-KC01</org_study_id>
    <secondary_id>UTHSCMS-12/0095</secondary_id>
    <nct_id>NCT01601873</nct_id>
  </id_info>
  <brief_title>Propaten Randomized Investigation on Cost-benefit and Efficacy</brief_title>
  <acronym>PRICE</acronym>
  <official_title>A Randomized Controlled Comparative Study on Efficacy and Cost-effectiveness of Heparin-bonded Versus Non-heparin-bonded Polytetrafluroethylene Hemodialysis Access Grafts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose for this study is to evaluate the patency and outcomes of conventional and
      heparin anticoagulant bonded arteriovenous grafts in patients with end stage renal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is a prospective, multi-institution, parallel-group, single-blinded,
      randomized-controlled, two-arm, effectiveness study comparing heparin-bonded (Propaten®)
      versus non-heparin-bonded arteriovenous grafts.

      Procedure: In patients without usable native vein, prosthetic arteriovenous grafts will be
      implanted for hemodialysis access. Patients will be randomized intraoperatively to either
      conventional (Gore® Stretch) or heparin-bonded grafts (Gore® Propaten).

      Course of Study: The study will accrue patients over the course of 5 years.

      Enrollment: Enrollment will consist of adult patients who require hemodialysis. If the
      patient cannot have a native vein arteriovenous fistula, the patient is a candidate for
      arteriovenous graft. Patients will be screened and consented preoperatively. If the
      intraoperative decision is made that the patient will require a graft, randomization will
      occur and the patient will be considered enrolled.

      Recruitment: The target population comprises of all adult patients aged 18 years and above
      with end stage renal disease requiring arteriovenous access for hemodialysis. The target for
      enrollment will be 200 patients.

      Risks: The standard or known adverse events associated with graft implantation include
      thrombosis, infection, pseudoaneurysm, hematoma, and venous stenosis. There are case reports
      of heparin sensitivity. The investigators do not expect any additional physical risks other
      than an unintentional disclosure of sensitive patient health information.

      Data Safety Monitoring: As the Principal Investigator of this study, Dr. Charlton-Ouw from
      the Department of Cardiothoracic and Vascular Surgery at The University of Texas at Houston
      Medical School will conduct the data safety monitoring of this study. He will annually meet
      with all other co-investigators to review the patients enrolled in this study. As part of the
      data safety monitoring plan, all patients enrolled until that point in time would be
      unblinded in order to review the outcomes. Interim analyses will be conducted at the one-year
      follow up time.

      IND#: The devices that will be used are already approved by the FDA and do not have IND#.

      Proposed Funding Source: The study is internally funded.

      Communication of Study Results: The communication of study results will occur only between
      authorized individuals who are listed to take part in the study through our department. The
      individuals who will take part in the study will acknowledge and adhere to the importance of
      patient safety and the protection of their private information. The results of this study
      will be analyzed and published after the approval of the principal investigator,
      co-investigators, and biostatistician in a peer-reviewed scientific journal and/or presented
      at an international/national scientific conference or meeting regardless of outcome.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Results from futility analysis conducted at planned interim time-point did not meet the study
    criteria for continuation.
  </why_stopped>
  <start_date type="Actual">November 9, 2012</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Graft Patency Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary-Assisted Graft Patency Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Primary-assisted graft patency is defined as a patent access with evidence of malfunction that requires an open surgical or endovascular intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Graft Patency Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary graft patency is defined as a functional access following intervention for thrombosis or after any interposition grafting for any reason including stenosis, aneurysm or pseudoaneurysm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Graft Patency Rate</measure>
    <time_frame>24 months after graft placement</time_frame>
    <description>Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary-Assisted Graft Patency Rate</measure>
    <time_frame>24 months after graft placement</time_frame>
    <description>Primary-assisted graft patency is defined as a patent access with evidence of malfunction that requires an open surgical or endovascular intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Graft Patency Rate</measure>
    <time_frame>24 months after graft placement</time_frame>
    <description>Secondary graft patency is defined as a functional access following intervention for thrombosis or after any interposition grafting for any reason including stenosis, aneurysm or pseudoaneurysm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complications or Morbidity Attributable to the Study</measure>
    <time_frame>at least 1 year but up to two years</time_frame>
    <description>Complication/morbidity associated with both types of interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Estimation and Analysis</measure>
    <time_frame>During the study period based on an average participant follow-up of 2 years after graft placement</time_frame>
    <description>Will be based on the difference between total cost analysed on the basis of the specific graft price, cost of re-intervention procedures if any, treatment of complications, hospital stay, etc., and compared for each study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) Comparison</measure>
    <time_frame>Participants would be followed for a period of 2 years after graft placement</time_frame>
    <description>Comparative assessment of quality of life reported by the patients in two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Postoperative Re-interventions</measure>
    <time_frame>at least 1 year but up to two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>PROPATEN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with heparin-bonded graft implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients undergoing ePTFE hemodialysis graft implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROPATEN</intervention_name>
    <description>Heparin-bonded graft implantation for hemodialysis vascular access</description>
    <arm_group_label>PROPATEN</arm_group_label>
    <other_name>Heparin-bonded hemodialysis graft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Graft</intervention_name>
    <description>non-heparin bonded conventional hemodialysis vascular access graft</description>
    <arm_group_label>Standard Graft</arm_group_label>
    <other_name>Conventional ePTFE hemodialysis graft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥18 years of all ethnicities

          -  End-stage Renal Disease stage 4 (GFR 15-29 ml/min 1.73m2) or stage 5 (GFR &lt;15ml/min
             1.73m2) per National Kidney Foundation guidelines

          -  Currently undergoing hemodialysis with a failure of previous access

          -  Expected to undergo hemodialysis within 6 months of presentation

        Exclusion Criteria:

          -  Unable/refuse to abide with follow-up

          -  Known hypercoagulability syndrome or a bleeding disorder

          -  On a previous anticoagulant treatment

          -  Intraoperative decision in favor of fistula instead of graft

          -  Pregnant or breast-feeding women

          -  A documented history of heparin induced thrombocytopenia or allergy

          -  Active infections

          -  Evidence or suspicion of central vein stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristofer M Charlton-Ouw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center, UT Medical School Department of Cardiothoracic and Vascular Surgery, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences (UAMS) &amp; Central Arkansas Veterans Healthcare System (CAVHS)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Ochsner Heart &amp; Vascular Institute Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiothoracic and Vascular Surgery and Memorial Hermann Heart and Vascular Institute - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiothoracic and Vascular Surgery; Memorial Hermann Hospital Southeast</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Charlton-Ouw KM, Nosrati N, Miller CC 3rd, Coogan SM, Safi HJ, Azizzadeh A. Outcomes of arteriovenous fistulae compared with heparin-bonded and conventional grafts for hemodialysis access. J Vasc Access. 2012 Apr-Jun;13(2):163-7. doi: 10.5301/JVA.2011.8715.</citation>
    <PMID>21983827</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <results_first_submitted>December 29, 2018</results_first_submitted>
  <results_first_submitted_qc>January 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2019</results_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Kristofer Charlton-Ouw</investigator_full_name>
    <investigator_title>Associate Professor, Department of Cardiothoracic and Vascular Surgery</investigator_title>
  </responsible_party>
  <keyword>Arteriovenous graft</keyword>
  <keyword>Propaten</keyword>
  <keyword>Heparin-bonded</keyword>
  <keyword>hemodialysis vascular access</keyword>
  <keyword>Surgical</keyword>
  <keyword>Arteriovenous Shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>De-identified data will be available following institutional review board approval</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT01601873/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>103 were enrolled, but only 97 started (a difference of 6 subjects). These 6 subjects who were enrolled but did not start the study presented to the day-surgery operating room but had not followed instructions to stop Coumadin; therefore, their cases were cancelled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PROPATEN</title>
          <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
        </group>
        <group group_id="P2">
          <title>Standard Graft</title>
          <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PROPATEN</title>
          <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
        </group>
        <group group_id="B2">
          <title>Standard Graft</title>
          <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="12.6"/>
                    <measurement group_id="B2" value="65" spread="11.9"/>
                    <measurement group_id="B3" value="64.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Graft Patency Rate</title>
        <description>Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.</description>
        <time_frame>12 months</time_frame>
        <population>1 in the propaten arm and 3 in the standard graft arm were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Graft Patency Rate</title>
          <description>Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.</description>
          <population>1 in the propaten arm and 3 in the standard graft arm were lost to follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.884</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary-Assisted Graft Patency Rate</title>
        <description>Primary-assisted graft patency is defined as a patent access with evidence of malfunction that requires an open surgical or endovascular intervention.</description>
        <time_frame>12 months</time_frame>
        <population>1 in the propaten arm and 3 in the standard graft arm were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Primary-Assisted Graft Patency Rate</title>
          <description>Primary-assisted graft patency is defined as a patent access with evidence of malfunction that requires an open surgical or endovascular intervention.</description>
          <population>1 in the propaten arm and 3 in the standard graft arm were lost to follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.946</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Secondary Graft Patency Rate</title>
        <description>Secondary graft patency is defined as a functional access following intervention for thrombosis or after any interposition grafting for any reason including stenosis, aneurysm or pseudoaneurysm.</description>
        <time_frame>12 months</time_frame>
        <population>1 in the propaten arm and 3 in the standard graft arm were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Graft Patency Rate</title>
          <description>Secondary graft patency is defined as a functional access following intervention for thrombosis or after any interposition grafting for any reason including stenosis, aneurysm or pseudoaneurysm.</description>
          <population>1 in the propaten arm and 3 in the standard graft arm were lost to follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.294</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Graft Patency Rate</title>
        <description>Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.</description>
        <time_frame>24 months after graft placement</time_frame>
        <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Graft Patency Rate</title>
          <description>Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.</description>
          <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.538</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary-Assisted Graft Patency Rate</title>
        <description>Primary-assisted graft patency is defined as a patent access with evidence of malfunction that requires an open surgical or endovascular intervention.</description>
        <time_frame>24 months after graft placement</time_frame>
        <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Primary-Assisted Graft Patency Rate</title>
          <description>Primary-assisted graft patency is defined as a patent access with evidence of malfunction that requires an open surgical or endovascular intervention.</description>
          <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.786</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Secondary Graft Patency Rate</title>
        <description>Secondary graft patency is defined as a functional access following intervention for thrombosis or after any interposition grafting for any reason including stenosis, aneurysm or pseudoaneurysm.</description>
        <time_frame>24 months after graft placement</time_frame>
        <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Graft Patency Rate</title>
          <description>Secondary graft patency is defined as a functional access following intervention for thrombosis or after any interposition grafting for any reason including stenosis, aneurysm or pseudoaneurysm.</description>
          <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complications or Morbidity Attributable to the Study</title>
        <description>Complication/morbidity associated with both types of interventions</description>
        <time_frame>at least 1 year but up to two years</time_frame>
        <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complications or Morbidity Attributable to the Study</title>
          <description>Complication/morbidity associated with both types of interventions</description>
          <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost Estimation and Analysis</title>
        <description>Will be based on the difference between total cost analysed on the basis of the specific graft price, cost of re-intervention procedures if any, treatment of complications, hospital stay, etc., and compared for each study arm.</description>
        <time_frame>During the study period based on an average participant follow-up of 2 years after graft placement</time_frame>
        <population>The cost data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Cost Estimation and Analysis</title>
          <description>Will be based on the difference between total cost analysed on the basis of the specific graft price, cost of re-intervention procedures if any, treatment of complications, hospital stay, etc., and compared for each study arm.</description>
          <population>The cost data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QoL) Comparison</title>
        <description>Comparative assessment of quality of life reported by the patients in two arms</description>
        <time_frame>Participants would be followed for a period of 2 years after graft placement</time_frame>
        <population>Qol data was collected, but because results of a planned interim futility analysis did not meet the study criteria for continuation, we do not believe analysis of the QoL data would be meaningful. Analysis of QoL data is an extremely onerous process that would take months to conduct. It is not worth the resources required to perform this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QoL) Comparison</title>
          <description>Comparative assessment of quality of life reported by the patients in two arms</description>
          <population>Qol data was collected, but because results of a planned interim futility analysis did not meet the study criteria for continuation, we do not believe analysis of the QoL data would be meaningful. Analysis of QoL data is an extremely onerous process that would take months to conduct. It is not worth the resources required to perform this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Postoperative Re-interventions</title>
        <time_frame>at least 1 year but up to two years</time_frame>
        <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPATEN</title>
            <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>Standard Graft</title>
            <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Postoperative Re-interventions</title>
          <population>2 in the propaten group and 3 in the standard graft group were lost to follow up.</population>
          <units>post-operative re-interventions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="5.0"/>
                    <measurement group_id="O2" value="2.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At least 1 year but up to two years (the study was stopped early for futility; therefore, some subjects were only followed for a year)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PROPATEN</title>
          <description>patients with heparin-bonded graft implantation
PROPATEN: Heparin-bonded graft implantation for hemodialysis vascular access</description>
        </group>
        <group group_id="E2">
          <title>Standard Graft</title>
          <description>patients undergoing ePTFE hemodialysis graft implantation
Standard Graft: non-heparin bonded conventional hemodialysis vascular access graft</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Unable to cannulate</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Graft site bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vascular steal requiring intervention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Failure to mature</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was stopped early for futility based on a pre-planned interim analysis and a Bayesian probability forecast incorporating all available information from a recent meta-analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kristofer Charlton-Ouw, MD</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>(713) 486-5117</phone>
      <email>Kristofer.CharltonOuw@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

